Published in J Rheumatol on September 01, 1997
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
Glycolipid antigen processing for presentation by CD1d molecules. Science (2001) 3.04
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum (2001) 2.96
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis (1973) 1.65
Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol (1988) 1.55
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Autologous matrix-induced chondrogenesis combined with platelet-rich plasma gel: technical description and a five pilot patients report. Knee Surg Sports Traumatol Arthrosc (2010) 1.51
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47
Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum (1997) 1.46
Serum levels of IgG, IgM, and IgA in rheumatoid arthritis. Ann Rheum Dis (1968) 1.45
Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol (1991) 1.45
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol (1997) 1.42
Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum (2000) 1.39
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol (2000) 1.37
Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol (1999) 1.36
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (2010) 1.34
Characterisation of human knee meniscus cell phenotype. Osteoarthritis Cartilage (2005) 1.34
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis (1999) 1.30
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) (1999) 1.28
Specific binding of the adenovirus terminal protein precursor-DNA polymerase complex to the origin of DNA replication. Nucleic Acids Res (1983) 1.24
HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol (1985) 1.23
Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum (1996) 1.21
Evaluation of T cell subsets with monoclonal antibodies in patients with rheumatoid arthritis. J Rheumatol (1982) 1.19
Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis (2008) 1.19
The antiperinuclear factor. Clin Exp Rheumatol (1991) 1.18
Subclinical involvement of the gut in undifferentiated spondylarthropathies. Clin Exp Rheumatol (1990) 1.16
Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol (1990) 1.16
A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. J Rheumatol (1993) 1.15
The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol (1988) 1.15
Letter: Levamisole in rheumatoid arthritis. Lancet (1976) 1.15
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis (2001) 1.13
Levamisole-induced adverse reactions in HLA B27-positive rheumatoid arthritis. Lancet (1978) 1.13
T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum (1999) 1.11
Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis (2002) 1.11
Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev (2005) 1.10
Involvement of the zygapophyseal joint in ankylosing spondylitis: relation to the bridging syndesmophyte. J Rheumatol (1999) 1.10
Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy--a prospective study. J Rheumatol (1993) 1.09
The occurrence of otitis media with effusion in Dutch pre-school children. Clin Otolaryngol Allied Sci (1990) 1.08
Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. Int J Immunopharmacol (1981) 1.06
The effect of preservation on the behaviour of homologous ossicular grafts. Acta Otolaryngol (1974) 1.06
CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis (2004) 1.06
Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am (1998) 1.06
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis (2004) 1.06
Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis (2001) 1.05
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus (2005) 1.05
Strontium 87m scanning of the sacroiliac joints in ankylosing spondylitis. Ann Rheum Dis (1972) 1.03
Clinical and radiographic features of Reiter's syndrome and inflammatory bowel disease related to arthritis. Curr Opin Rheumatol (1990) 1.03
Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout. Ann Rheum Dis (1973) 1.03
Differential proteome analysis of normal and osteoarthritic chondrocytes reveals distortion of vimentin network in osteoarthritis. Osteoarthritis Cartilage (2007) 1.01
Antigen-presenting capacity of rheumatoid synovial fibroblasts. Immunology (1994) 1.01
Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol (1993) 1.01
Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) (2008) 1.00
Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol (1996) 0.98
Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis (2005) 0.97
Chemical agents and enzymes used for the extraction of gut lymphocytes influence flow cytometric detection of T cell surface markers. J Immunol Methods (2000) 0.97
A double-linear immunodiffusion method for the quantitation of proteins. Clin Chim Acta (1970) 0.97
HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol (1985) 0.96
Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs. J Rheumatol (1991) 0.96
Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. Osteoarthritis Cartilage (2003) 0.96
Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis (2005) 0.96
The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. J Rheumatol (1991) 0.96
Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis (2002) 0.96
Numerical scoring systems for the progression of osteoarthritis of the finger joints. Rev Rhum Engl Ed (1995) 0.95
Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis (2003) 0.95
Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis (2004) 0.95
Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol (1995) 0.94
The gut in the spondyloarthropathies. J Rheumatol (1990) 0.94
Repeat ileocolonoscopy in reactive arthritis. J Rheumatol (1987) 0.94
Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol (2002) 0.94
HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut inflammation. J Rheumatol (1987) 0.94
Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease. J Rheumatol (1991) 0.94
Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis (2001) 0.94
Comparison of serum salicylate levels and gastro-intestinal blood loss between salsalate (Disalcid)and other forms of salicylates. Scand J Rheumatol (1981) 0.94
Experience and recommendations for treatment schedule of levamisole in rheumatoid arthritis. J Rheumatol Suppl (1978) 0.93
Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis (2008) 0.93
The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol (2001) 0.93
The combination of microfracture and a cell-free polymer-based implant immersed with autologous serum for cartilage defect coverage. Knee Surg Sports Traumatol Arthrosc (2011) 0.93